



LifeScienceNet Düsseldorf meets BioCologne

# Innovations in fatty liver research and therapy

Liver fibrosis • biomarker • drug development



**Symposium**

**on Thursday, May 22, 2025**

**10.25 h–15.00 h**

Life Science Center, Conference Area  
Merowingerplatz 1, 40225 Düsseldorf

Registration  
online until  
May 20<sup>th</sup>:



Supported by:



**Organizer:**

LifeScienceNet Düsseldorf and BioCologne,  
c/o Life Science Center Düsseldorf, Merowingerplatz 1, 40225 Düsseldorf,  
info@lifescience-dus.de, www.lifescience-dus.de

**Registration:**

[lifescience-dus.de/lifesciencenet-duesseldorf-meets-biocologne](https://lifescience-dus.de/lifesciencenet-duesseldorf-meets-biocologne)

# Symposium: Innovations in fatty liver research and therapy

## Liver fibrosis · biomarker · drug development

The prevalence of fatty liver disease mirrors the global burden of the metabolic syndrome, while numbers alarmingly continuing to rise. Understanding the underlying disease mechanisms with cutting-edge human models, refining targeted biomarker analysis, and discovering innovative drug targets are key for the development of effective therapies.

### Program:

10.25 – 10.30

#### Welcome

Life Science Net Düsseldorf, BioCologne

10.30 – 10.40

#### Introduction

Prof. Dr. Juergen Eckel, CEO, CMR CureDiab Metabolic Research GmbH, Düsseldorf

10.40 – 11.00

#### Hepatic energy metabolism in steatotic liver diseases: mechanisms and therapeutic targets

Dr. Bedair Dewidar, Postdoctoral Researcher, German Diabetes Center, Düsseldorf

11.00 – 11.20

#### Immunometabolic profiles of tissue-resident and monocyte-derived hepatic macrophage subsets during MASLD development

Dr. Bruno Guigas, Associate Professor, Leiden University Medical Center, Leiden, NL

11.20 – 11.40

#### The development of a liver-chip for detection of drug-induced liver injury and fatty liver disease

Dr. Lorna Ewart, CSO, Emulate Inc. Boston, US

11.40 – 12.00

#### FibroPaths liver: combinatorial approach of in silico, 2D and 3D ex vivo methods for the identification of novel therapeutic targets in human liver diseases

PD. Dr. Jan Fiedler, Group Leader Molecular Biomarkers for Disease Modelling, Fraunhofer Institute for Toxicology and Experimental Medicine, Hannover

Lunch Break

13.00 – 13.20

#### The use of artificial intelligence for the analysis of histological imaging data

Dr. Tobias Seraphin, Clinical Scientist & Resident, Department of Gastroenterology, Hepatology, and Infectious Diseases, Düsseldorf University Hospital, Düsseldorf

13.20 – 13.40

#### Dissecting Fibrotic Pathways: the extracellular matrix as a driver and target

Prof. Dr. Gerhard Sengle, Group Leader Department of Pediatric and Adolescent Medicine, University Hospital Cologne, Center for Molecular Medicine Cologne

13.40 – 14.00

#### From bench to bedside and back to the future: lifecycle of pre-clinical and clinical liver fibrosis biomarkers

Dr. Dimitar Tasev, CSO, GBS, Leiden

Coffee Break

14.20 – 14.40

#### Role of Sema3A in early MASLD

Prof. Dr. Eckhard Lammert, Head of Institute of Metabolic Physiology, Heinrich Heine University, Düsseldorf

14.40 – 15.00

#### New MASLD drugs

Prof. Dr. Juergen Eckel, CEO, CMR CureDiab Metabolic Research, Düsseldorf

15.00

#### Networking

In cooperation with:

